SLC5A2 and Abnormal renal physiology: Sugiyama et al. reported the renoprotective effect of SGLT2 inhibitor therapy in patients with type 2 diabetes and renal dysfunction (CKD stages 3b-4) in a relatively small number of study subjects (n = 42), including 5 patients who received tofogliflozin [31].